Zelgen(688266)2024-07-25 08:08Group 1: Company Overview and Activities - Suzhou Zejing Biopharmaceutical Co., Ltd. is actively engaging with investors through various activities, including analyst meetings and one-on-one communications [2] - The company is focused on enhancing its management and control over GENSUN, a subsidiary aimed at new drug development in the U.S. [3] Group 2: Drug Development Progress - GENSUN is developing multiple candidate antibody drugs, including ZG005 and ZG006, which have received clinical trial approvals in China and the U.S. [3] - ZG006 is the world's first tri-specific antibody targeting DLL3, currently in Phase I clinical trials with smooth enrollment progress [4] - ZG005 has shown promising results in early clinical studies, with a total of 79 participants, where 43% had previously received at least two lines of systemic therapy [5] Group 3: Clinical Trial Results - In the clinical trial for ZG005, the objective response rate (ORR) was 43% and the disease control rate (DCR) was 81%, particularly in the 20 mg/kg dose group, which achieved an ORR of 63% [5] - ZG005 demonstrated good tolerability and safety, with 63.3% of participants experiencing treatment-related adverse events [6] Group 4: Future Developments - The company is accelerating the development of JAK inhibitors for autoimmune diseases, with ongoing Phase III trials for JAK inhibitors in severe alopecia areata [7] - The application for recombinant human thyroid-stimulating hormone (rhTSH) has been accepted for review, aimed at differentiated thyroid cancer patients post-thyroidectomy [8] Group 5: Upcoming Presentations - ZGGS18's clinical research data will be presented at the 2024 ASCO meeting, with 21 participants enrolled in the trial, showing an ORR of 5.3% and a DCR of 42.1% [9]